论文部分内容阅读
目的比较20 mg与40 mg阿托伐他汀对缺血性心肌病(ischemic cardiomyopathy,ICM)患者血清8-羟基脱氧鸟嘌呤(8-hydroxy deoxyguanosine,8-OHdG)水平的影响。方法按随机数字表法将246例患者分为两组:阿托伐他汀20 mg/d治疗组(20 mg治疗组,n=124)和40 mg/d治疗组(40 mg治疗组,n=122)。1年随访期。结果患者均完成1年随访,在随访期内两组药物应用方面差异无显著性差异(P>0.05),两组横纹肌溶解、药物性肝炎及其他不良反应比较差异无统计学意义(P>0.05)。组内比较:两组患者总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)均较治疗前明显降低(P<0.05);治疗后,40 mg治疗组超敏-C反应蛋白(high-sensitive Creactive protein,hs-CRP)、脑利钠肽(brain natriuretic peptide,BNP)和8-Ohd G水平明显低于治疗前,差异具有统计学意义(P<0.05)。组间比较:治疗后40 mg治疗组的hs-CRP、BNP和8-OHdG较20 mg治疗组明显降低,差异有统计学意义(P<0.05)。结论阿托伐他汀的抗氧化作用与剂量存在关系,40 mg阿托伐他汀较20 mg阿托伐他汀的抗氧化作用明显。
Objective To compare the effects of 20 mg and 40 mg atorvastatin on serum 8-hydroxy deoxyguanosine (8-OHdG) levels in patients with ischemic cardiomyopathy (ICM). Methods According to random number table, 246 patients were divided into two groups: Atorvastatin 20 mg / d treatment group (20 mg treatment group, n = 124) and 40 mg / d treatment group (40 mg treatment group, n = 122). 1 year follow-up period. Results All patients were followed up for 1 year. There was no significant difference in drug application between the two groups during follow-up (P> 0.05). There was no significant difference in rhabdomyolysis, drug-induced hepatitis and other adverse reactions between the two groups (P> 0.05 ). Comparing the two groups, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in both groups were significantly lower than those before treatment (P <0.05); after treatment, 40 mg The levels of high-sensitive Creactive protein (hs-CRP), brain natriuretic peptide (BNP) and 8-Ohd G were significantly lower than those before treatment (P < 0.05). Compared between two groups, the hs-CRP, BNP and 8-OHdG in the 40 mg treatment group were significantly lower than those in the 20 mg treatment group after treatment (P <0.05). Conclusions Atorvastatin has an anti-oxidative effect on the dose. Atorvastatin 40 mg has a more significant anti-oxidant effect than atorvastatin 20 mg.